Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.
Also called NCT02827500
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 104 participants
- Sponsor
- Registry
-
NCT02827500
-
- Other papers using this trial's data
- PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02827500. Randomized; no masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2018-10-15 (actual). Results posted on 2019-10-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
- Acronym
- PRIME-HF
- Condition
- Heart Failure
- Intervention (Drug)
- ivabradine
- Intervention (Other)
- Usual Care
- Lead sponsor
- Duke University
- Collaborator
- Amgen
Record details
- Record id
cardio:ct-nct02827500- Content hash
e76c42ffb6f484326bb6daecd1440ce7a948dbeed31a49e1edadb8b052f27032